Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced a new shareholder agreement involving the placement of new H shares under a general mandate. The agreement, which was entered into on June 5, 2025, involves Goldman Sachs and Citigroup as the overall coordinators and placing agents. This placement is part of a strategic move to raise capital, with the new shares to be listed on the Hong Kong Stock Exchange under stock code 6990. The company has clarified that there are no intentions to register these securities under the U.S. Securities Act or conduct a public offering in the United States. Additionally, proposed amendments to the articles of association have been announced.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。